These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 26312959)

  • 1. Triple dosing with high doses of buprenorphine: Withdrawal and plasma concentrations.
    Hvittfeldt E; Charlotte G; Fridolf I; Håkansson A
    J Opioid Manag; 2015; 11(4):319-24. PubMed ID: 26312959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphine.
    Kuhlman JJ; Levine B; Johnson RE; Fudala PJ; Cone EJ
    Addiction; 1998 Apr; 93(4):549-59. PubMed ID: 9684393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An evidence-based recommendation to increase the dosing frequency of buprenorphine during pregnancy.
    Caritis SN; Bastian JR; Zhang H; Kalluri H; English D; England M; Bobby S; Venkataramanan R
    Am J Obstet Gynecol; 2017 Oct; 217(4):459.e1-459.e6. PubMed ID: 28669739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioavailability of buprenorphine from crushed and whole buprenorphine (subutex) tablets.
    Simojoki K; Lillsunde P; Lintzeris N; Alho H
    Eur Addict Res; 2010; 16(2):85-90. PubMed ID: 20130408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Buprenorphine tablet versus liquid: a clinical trial comparing plasma levels, efficacy, and symptoms.
    Chawarski MC; Moody DE; Pakes J; O'Connor PG; Schottenfeld RS
    J Subst Abuse Treat; 2005 Dec; 29(4):307-12. PubMed ID: 16311183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics of a buprenorphine subcutaneous depot formulation (CAM2038) for once-weekly dosing in patients with opioid use disorder.
    Haasen C; Linden M; Tiberg F
    J Subst Abuse Treat; 2017 Jul; 78():22-29. PubMed ID: 28554599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hair analysis for long-term monitoring of buprenorphine intake in opiate withdrawal.
    Pirro V; Fusari I; Di Corcia D; Gerace E; De Vivo E; Salomone A; Vincenti M
    Ther Drug Monit; 2014 Dec; 36(6):796-807. PubMed ID: 24713865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of differential doses of buprenorphine for long term pharmacotherapy among opiate dependent subjects.
    De S; Jain R; Ray R; Dhawan A; Varghese ST
    Indian J Physiol Pharmacol; 2008; 52(1):53-63. PubMed ID: 18831352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic Evaluation of Once-Weekly and Once-Monthly Buprenorphine Subcutaneous Injection Depots (CAM2038) Versus Intravenous and Sublingual Buprenorphine in Healthy Volunteers Under Naltrexone Blockade: An Open-Label Phase 1 Study.
    Albayaty M; Linden M; Olsson H; Johnsson M; Strandgården K; Tiberg F
    Adv Ther; 2017 Feb; 34(2):560-575. PubMed ID: 28070862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single high-dose buprenorphine for opioid craving during withdrawal.
    Ahmadi J; Jahromi MS; Ghahremani D; London ED
    Trials; 2018 Dec; 19(1):675. PubMed ID: 30526648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Examining the limits of the buprenorphine interdosing interval: daily, every-third-day and every-fifth-day dosing regimens.
    Petry NM; Bickel WK; Badger GJ
    Addiction; 2001 Jun; 96(6):823-34. PubMed ID: 11399214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of the combination tablet of buprenorphine and naloxone.
    Chiang CN; Hawks RL
    Drug Alcohol Depend; 2003 May; 70(2 Suppl):S39-47. PubMed ID: 12738349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma concentrations of buprenorphine 24 to 72 hours after dosing.
    Chawarski MC; Schottenfeld RS; O'Connor PG; Pakes J
    Drug Alcohol Depend; 1999 Jun; 55(1-2):157-63. PubMed ID: 10402160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Maintaining opioid abstinence long after inpatient treatment with opioid substitution in an addictology hospital unit].
    Bouab O; Lahmek P; Meunier N; Aubin HJ; Michel L
    Rev Med Brux; 2013; 34(3):132-40. PubMed ID: 23951853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period.
    Correia CJ; Walsh SL; Bigelow GE; Strain EC
    Psychopharmacology (Berl); 2006 Dec; 189(3):297-306. PubMed ID: 17013637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined buprenorphine and chlonidine for short-term opiate detoxification: patient perspectives.
    Wallen MC; Lorman WJ; Gosciniak JL
    J Addict Dis; 2006; 25(1):23-31. PubMed ID: 16597570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nalmefene Mistakenly Prescribed to Reduce Alcohol Consumption in Patients Under Buprenorphine Substitution Therapy Resulting in Acute Opioid Withdrawal: Management in an Emergency Setting.
    Pélissier F; Rougé Bugat ME; Nubukpo P; Franchitto N
    J Clin Psychopharmacol; 2016 Feb; 36(1):100-3. PubMed ID: 26658085
    [No Abstract]   [Full Text] [Related]  

  • 18. A comparison of four buprenorphine dosing regimens using open-dosing procedures: is twice-weekly dosing possible?
    Petry NM; Bickel WK; Badger GJ
    Addiction; 2000 Jul; 95(7):1069-77. PubMed ID: 10962771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of four buprenorphine dosing regimens in the treatment of opioid dependence.
    Petry NM; Bickel WK; Badger GJ
    Clin Pharmacol Ther; 1999 Sep; 66(3):306-14. PubMed ID: 10511067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of efficacy between buprenorphine and tramadol in the detoxification of opioid (heroin)-dependent subjects.
    Chawla JM; Pal H; Lal R; Jain R; Schooler N; Balhara YP
    J Opioid Manag; 2013; 9(1):35-41. PubMed ID: 23709302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.